Esophageal squamous cell ... is crucial for developing effective therapies. This discovery provides new insights into the ...

Bart Frazzitta was told he had a 5% chance of surviving esophageal cancer. Twenty-five years later, he's still here and ...

Aspirin reduced recurrence by 50% in PIK3CA-mutated colorectal cancer, the DCISionRT test earned FDA breakthrough status for predicting radiotherapy benefit in DCIS, and nivolumab plus chemotherapy ...

University of Kentucky Markey Cancer Center researchers have discovered a promising new way to combat therapy-resistant ...

Esophageal cancer five-year relative survival ... radiation therapy and targeted therapies. The NCI estimates that lung and bronchus cancer caused around 125,070 U.S. deaths in 2024.

Patients who traveled to high-volume centers for esophagectomy experienced better outcomes than those who sought treatment ...

We have summarized in this article the current state of combination therapy of approved targeted drugs and irradiation. Since the introduction of the first targeted compounds almost (trastuzumab ...

With cutting-edge research and regulatory support, Spain has become a leader in oncology in Europe. Innovations such as CAR-T ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

University of Kentucky Markey Cancer Center researchers have discovered a promising new way to combat therapy-resistant ...